STRS Ohio’s Aclaris Therapeutics ACRS Stock Holding History

STRS Ohio’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$431K	Buy	81,400 +65,400	+409%	+$292K	﹤0.01%	1224
2026 Q1	$60K	Buy	+16,000	New	+$54K	﹤0.01%	1901
2024 Q2	–	Sell	-264,700	Closed	-$328K	–	1950
2024 Q1	$328K	Buy	264,700 +71,700	+37%	+$85.5K	﹤0.01%	1411
2023 Q4	$202K	Buy	193,000 +138,900	+257%	+$424K	﹤0.01%	1555
2023 Q3	$370K	Hold	54,100	–	–	﹤0.01%	1385
2023 Q2	$561K	Buy	54,100 +4,200	+8%	+$38K	﹤0.01%	1213
2023 Q1	$403K	Buy	49,900 +13,500	+37%	+$171K	﹤0.01%	1409
2022 Q4	$573K	Buy	36,400 +16,500	+83%	+$265K	﹤0.01%	1250
2022 Q3	$313K	Buy	19,900 +2,000	+11%	+$31.5K	﹤0.01%	1481
2022 Q2	$249K	Buy	+17,900	New	+$251K	﹤0.01%	1541
2021 Q4	–	Sell	-6,700	Closed	-$120K	–	2179
2021 Q3	$120K	Sell	6,700 -10,200	-60%	-$164K	﹤0.01%	1908
2021 Q2	$296K	Buy	+16,900	New	+$384K	﹤0.01%	1722
2017 Q2	–	Sell	-21,100	Closed	-$629K	–	1926
2017 Q1	$629K	Buy	+21,100	New	+$608K	﹤0.01%	1220
2016 Q4	–	Sell	-8,100	Closed	-$207K	–	1910
2016 Q3	$207K	Buy	8,100 +5,100	+170%	+$108K	﹤0.01%	1544
2016 Q2	$55K	Buy	3,000 +1,100	+58%	+$21.8K	﹤0.01%	1754
2016 Q1	$36K	Hold	1,900	–	–	﹤0.01%	1792
2015 Q4	$51K	Buy	+1,900	New	+$37K	﹤0.01%	1791

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

STRS Ohio's ACRS Position: Q2 2026 in Review

STRS Ohio increased its Aclaris Therapeutics (ACRS) stake by 409% in Q2 2026, buying an estimated $292K and bringing the position to 81,400 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

STRS Ohio first reported a position in ACRS in Q4 2015 and has held it in 17 quarters since. The position peaked at $629K in Q1 2017. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

STRS Ohio held 81,400 shares of Aclaris Therapeutics worth $431K as of Q2 2026.
STRS Ohio bought 65,400 Aclaris Therapeutics shares in Q2 2026, an estimated $292K.
Aclaris Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1224 holding.
STRS Ohio first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 17 quarters since.
STRS Ohio's Aclaris Therapeutics position peaked at $629K in Q1 2017.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.